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Inappropriate use of Promethazine and Promethazine-containing 
products in children under the age of three years in Harare,
Zimbabwe
*A MARUME, *TG MUVIRIMI, **K CHITINDINGU, *1 MUTINGWENDE
Abstract
Objectives: To determine whether there was inappropriate use o f promethazine, Stopayne® or Goldgesic® in children 
under three (3) years o f age in Harare, and to measure its extent. Inappropriate referred to administering these 
medicines to children under the age o f two (2) years for any indication or the administering o f these medicines to an 
otherwise healthy child less than three (3) years old for sedation purposes.
Design: A descriptive cross-sectional study carried out between May and July 2010.
Setting: Retail pharmacies in Harare, Zimbabwe.
Results: The percentages of pharmacy personnel who indicated that parents request these syrups for sedation purposes 
in their children were: 20.8% promethazine; 18.9% Stopayne®; and 9.6% Goldgesic®. With respect to parents, it was 
found that 25% administered these syrups to children aged below 2 years. O f the parents who administered these syrups 
to their children about 7.7% did so for sedation purposes.
Conclusion: There was significant inappropriate use o f all 3 syrups in children under the age o f 3 years (p<0.05). Direct 
evidence was seen in that pharmacy personnel dispensed these medicines for use in infants and parents administered 
these syrups to infants.
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Introduction
In Z im babw e, p rom ethazine, Stopayne® and 
Goldgesic® syrups are classified as pharmacy drugs (P) 
by the Medicines Control Authority o f Zimbabwe 
(MCAZ). A pharmacy drug, according to the 
Medicines and Allied Substances Control Act (1991),8 
is a medicine that is to be sold only, by a pharmacist, 
any person under the continuous personal supervision 
o f a pharmacist, from licensed pharmacies or by a 
wholesale dealer with a valid wholesale dealer's 
permit. Promethazine, Stopayne® and Goldgesic® 
syrups are available over-the-counter (OTC), without 
need for a prescription.
Promethazine (Phenergan®) is available in various
dosage forms, but is mostly dispensed for children as a 
syrup containing 5mg o f promethazine hydrochloride 
per 5mL of the medicine. This drug is indicated for 
symptomatic relief o f allergy such as hay fever and 
urticaria, for premedication, emergency treatment o f 
anaphylactic reactions, and motion sickness.9 The 
British National Formulary, however, does not 
recommend the use o f hypnotics/ sedatives in children. 
Promethazine exerts its anti-histamine effects through 
blockade o f histamine (H,) receptors, which are 
distributed in the brain, smooth muscle, heart as well as 
capillary endothelium.
The syrups have alcohol in their formulations, with 
Goldgesic® having 12.5% (m/v) and Stopayne® having 
o f 10% (m/v). Goldgesic® and Stopayne® are indicated
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for the relief o f mild to moderate pain associated with 
fever. Paracetamol is a centrally acting analgesic and is 
also an anti-pyretic. Codeine is also a centrally acting 
analgesic and it exerts its effects through opioid 
receptor stimulation in the brain and spinal cord.9
The over-the-counter availability  o f  these 
preparations may promote the perception that they are 
safe. However, promethazine use is not recommended 
for children younger than the age of 2 years, whilst 
codeine is not recommended for infants under the age 
o f 1 year.9
The adverse effects reported with promethazine use 
in children include respiratory depression, cardiac 
arrest, sleep apnoea and seizures.1 The relative 
immaturity o f drug metabolising enzyme systems in 
young children is a factor that may increase the adverse 
effects of drugs such as promethazine and codeine, 
especially in children younger than 6 months. In 
addition, alteration of hepatic enzymes by illnesses or 
concurrent drug therapy (such as paracetamol) may 
further alter metabolism of a drug such as codeine, and 
increase the risk of an adverse reaction because of 
accumulation of the drug. The impact o f these adverse 
reactions would be minimal if  parents administered 
these over-the-counter m edications only for 
appropriate indications and only in children over 2 
years o f age.
Administration of promethazine to infants less than 
two years of age carries a grave health risk. 
Promethazine has been implicated in Sudden Infant 
Death Syndrome (SIDS)6 and in the generation of sleep 
apnoeas in normal infants (Khan, 1982).
A study carried out in Harare showed 70% of OTC 
staff had little knowledge about the toxicity of 
promethazine. In light of the findings o f these studies, it 
was therefore, important to determine pharmacy staff 
dispensing practices with regard to promethazine and 
the other promethazine-containing preparations. 
Research into inappropriate use o f these medicines had 
not been done before in Zimbabwe. The findings from 
studies carried out in other countries could not simply 
be extrapolated to Zimbabwe because common 
knowledge, attitudes and perceptions of people may 
vary from one country to another.123 The results o f this 
study might stimulate research in areas related to this 
subject consequently the category o f distribution of 
preparations with promethazine might be changed by 
MCAZ into either pharmacist initiated medicines 
(PIMs) or prescription preparations. According to the 
Medicines and Allied Substances Control Act Statutory 
Instrument 150, PIMs were medicines that did not 
require a medical practitioner's prescription, but might 
only be supplied on the recommendation of a 
pharmacist who showed maintain proper records 
relating thereto.
Materials and Methods
This was a cross sectional study carried out between
May and July 2010 in Harare, Zimbabwe. Information 
obtained from the Medicines Control of Authority of 
Zimbabwe (MCAZ) states that there are 152 
retail/community pharmacies in Harare as o f May 
2010 The study population was taken from pharmacies 
in Harare, and included all of the following pharmacy 
personnel: pharm acists, pharm acy technicians, 
dispensary assistants, over the counter (OTC) 
assistants and parents, child care-givers with children 3 
years old and younger who would have visited the 
pharmacy during the research period.
Use of promethazine-containing syrups was 
investigated in children 3 years old and younger in an 
attempt to determine whether these medicines were 
being given to children for real or perceived 
hyperactivity. Hyperactivity was more perceivable in 
an older child than in a young infant hence 3 years of 
age was the chosen upper limit. Some signs of 
hyperactivity included inability to focus, excessive 
talking, inability to relax, and temper tantrums. The 
average age of children in the study was 16 months 
(standard deviation 9.9 months, median 16 months).
Ethical Approval
Ethical approval for this study was sought from the 
Joint Parirenyatwa Hospital and College o f Health 
Sciences Research Ethics Committee. Participants' 
confidentiality was maintained.
Statistics
Sample sizes were calculated using Pocock's formula 
(Rosner, 2000). Minimum required sample size of 
parents or childcare-givers was determined as 960, 
given that the prevalence o f inappropriate use 50%, 
significance level 5% and 10% margin o f error.
The minimum required sample size o f pharmacy 
personnel to be interviewed was determined as 530, 
given probability o f having little knowledge 70%, 5% 
significance level, population size o f 152 pharmacies 
(MCAZ list o f  licensed premises, 2010).
Sample sizes were calculated using the following 
equation that incorporated the total population:
n = Nx Z^ 2 x p ( l - p )
> d2( N - l )  + Z j p ( l - p )
Where n= sample size, p=probability o f obtaining the 
outcome o f interest Za/22 = the z-score for a 5% 
significance level (1.96), d= the desired interval 
0,123, N=total population.
Two dilferent interviewer-administered questionnaires 
were used to obtain data from exit parents or caregivers 
o f retail/community pharmacies in Harare, and the 
other to obtain information from pharmacy personnel. 
Exit parents or caregivers o f retail/community
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pharmacies in Harare and the pharmacy personnel were 
conveniently selected from all the 152 pharmacies in 
Harare. The questionnaires incorporated both close- 
ended and open- ended questions. Demographic 
questions included sex, number o f years in practice (for 
pharmacy staff only) and profession. The rest o f the 
questions were meant to assess knowledge and 
practices pertaining to use of promethazine, Stopayne* 
and Goldgesic® syrups.
Data were checked for completeness and consistency, 
before being computed and analysed using the software 
package Epi-info®. The X2 test was then used to 
determine the significance o f any association between 
certain categorical values. The P-value used was 0.05.
Results
Five hundred and thirty pharmacy personnel took part 
in this study: 190 (35.8%) pharmacists, 105 (19.8%) 
pharmacy technicians and 235 (44.4%) pharmacy 
assistants. The average number o f years in practice 
was 5.5 years, (standard deviation 4.8 years, median 
4.0 years).
The majority o f pharmacy personnel 460 (86.8%) 
had each dispensed all three medicines (promethazine, 
Stopayne® and Goldgesic® syrups). All pharmacists had 
previously dispensed all the 3 syrups.
All pharmacy stafflisted some correct indications for 
all syrups that they had dispensed. However, some 
personnel 37.8% (200) also listed off-license uses or 
totally incorrect indications for at least one o f these 
medicines:
Table I: Off-license/incorrect indications listed by 
personnel.
Syrup Off-license use/ 
Inco rrec t indication
L icensed use/ 
C o rrec t ind ication
Promethazine influenza, diarrhoea allergy, motion
goosebumps, sedation sickness/vomiting
Stopayne® diarrhoea, colds, relief o f  m ild to
inflammation m oderate pain and fever
Goldgesic® diarrhoea, colds, relief o f  m ild to
Inflammation moderate pain and fever
Table I shows the correct indications/licensed uses and the incorrect
indication/off-licence uses of promethazine, Stopayne® and Goldgesic® by 
pharmacy personnel.
All participants (100%) indicated that parents come in 
and asked for these syrups for their children. 
Stopayne® was the most requested (n=48), followed 
by promethazine (n=43) and then Goldgesic® (n=28). 
Apart from the above stated indications (licensed and 
unlicensed), pharmacy personnel reported that parents 
were requesting these syrups for sedation.
Table II: Pharmacy personnel who reported parent 
requests for syrups for sedation purpose in children.
Syrup n=530 (% )
Promethazine 110 20.8
Stopayne® 100 18.9
Goldgesic® 59 9.4
Table shows the requests that were made by parents/caregivers for the three 
syrups. Promethazine was the most requested by parents/caregivers from 
retail/community pharmacies.
All but 41 (7.74%) o f the participants indicated that 
they counselled parents concerning the use o f these 
medicines (92.45%). The counselling given was found 
to be in line with manufacturer literature (Package 
Inserts) as well as basic pharmacology, e.g., warning 
about drowsiness with all three syrups (273/530); 
constipation with Stopayne®and Goldgesic® (64/530).
The majority 476 (89.81%) of personnel were aware 
that these medicines have a recommended minimum 
age. However, fewer personnel stated the correct age, 
with Goldgesic® being the least known about medicine. 
78 (41.05%) pharmacists were unable to state the 
correct age for each o f the three medicines, whilst 243 
(71.47) o f the non-pharmacist personnel could not state 
the correct minimum age for all three.
O f the 476 personnel who stated that there is an age 
limit, 264 (55.46%) said that they dispense these 
medicines nevertheless for use in infants. Reasons for 
dispensing these syrups to infants include: the 
medicine being on a prescription (n=136); benefit 
outweighing risk in serious cases (n=36); there being 
no alternative medicine for the child's symptoms 
(n=27); and child approaching 2 years o f age (n= 18). 
Chi-squared tests were performed to determine the 
significance o f any association between certain 
categorical values, using p-value set at 0.05. A 
significant association was found between ‘non­
pharmacists’ and ‘not knowing the correct minimum 
age for Stopayne syrup’ (p=0.03).
For those parents who had administered any o f the 
three syrups to their babies (n=660), the follow 
observations were made as shown in Table III below:
Table III: The syrups which parents administered to 
their children.
S yru p Frequency n  (% )
Promethazine 271 22.05
Stopayne® 299 24.33
Goldgesic® 90 7.32
Had never administered any o f  the 3 569 46.30
Promethazine was administered mostly for allergies
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(n=140), and also vomiting (n=60). Other uses were 
off-license for infants, i.e., cough and cold (n=30) or for 
a completely incorrect indication, i.e., fever (n=30). 
Stopayne’ was given mostly for pain (n= 15), as well as 
fever (n= ll); allergies (n=8); sedation (n=26); coughs 
and colds (n=27); and stomach ache (n=17). 
Goldgesic® was given for pain (n=17) and stomach 
ache (n=31).
Off-license use of medicine or administration for 
inappropriate indication was found with 50% (330) o f 
the parents who used these medicines. Furthermore, o f 
the 660 parents who had administered at least one of 
these medicines to their children, 241 (36.52%) o f them 
had children below two years of age.
Paracetamol syrup was the only other medication that 
parents reported having given to their children 
(n=303). Chi-squared tests revealed no association 
between any categorical values. Again, p-value was set 
at 0.05.
Discussion
From the study, there was strong evidence to suggest 
high levels of inappropriate use of promethazine and 
promethazine-containing medicines in children less 
than three (3) years of age in Harare. This was 
indirectly portrayed by the lack o f knowledge about the 
minimum age o f administration o f promethazine and 
prom ethazine-containing medicines (41.05% of 
pharmacists and 71.47% of other pharmacy personnel). 
More direct evidence was seen in the fact that more 
than half (55.46%) of the personnel who were aware 
that there is a minimum age, dispensed these medicines 
to parents in spite of this knowledge. Over-the-counter 
medicines such as those under investigation in this 
study might therefore be perceived by pharmacists as 
very safe for use, even in infants. The assertion by 
parents pharmacists and other pharmacy personnel that 
they give these syrups to children when the “benefit 
outweighs the risk”, showed that, any adverse effects of 
promethazine-containing medicines in children go 
largely uninvestigated or unreported in this country. 
Indeed, a literature search on this subject in Zimbabwe 
yielded no results.
Amongst the most cited reasons listed by pharmacy 
personnel for dispensing these medicines to infants in 
spite o f there being a minimum age, was the drug being 
on a doctor's prescription. Unfortunately, from the data 
collected there was no way of determining whether any 
o f these pharmacists ever queried such prescriptions 
with medical practitioners. If  they generally did not 
query such prescriptions, then this was in line with 
doctor-pharmacist relationship studies that showed 
doctors had poor or little experience o f pharmacists 
providing clinical advisory services to them (Bernstein 
etal, 1978; Paul etal, 2003, Nelson etal, 1978).
Another reason stated for dispensing promethazine- 
containing medicines for infants was a (real or 
perceived) lack of alternative medicines. Though not 
always available or affordable, there were indeed
a lte rn a tiv e s . Som e p o ss ib le  a lte rn a tiv e s  to 
promethazine were recommended as follows: vomiting 
should be ideally treated with anti-emetics only when 
the cause o f vomiting is known, because anti-emetics 
may delay diagnosis of serious illness. Pharmacists 
should generally refer cases o f vomiting lasting more 
than 24 hours, and not improving, to a doctor (Leung, 
2007).
Airway congestion could be combated with OTC 
nasal saline (suitable for all ages). Coughs can be 
treated in children over I year o f age with, medicines 
containing chlorpheniramine, dextromethorphan or 
codeine. However, products containing combinations 
o f these drugs are no longer recommended for use in 
children under 6 years o f age, with particular mention 
going to promethazine-codeine combinations (FDA 
Centre for Drug Evaluation and Safety, 2008). Anti­
motility agents were not recommended for acute 
diarrhoea in young children (British National 
Formulary, 2007). Instead, acute diarrhoea, which is 
often caused by infection, should be left to run its 
course, administering oral rehydration salt solution to 
the infant. Referral to a medical doctor is necessary if 
diarrhoea for persists after 72 hours (Edwards, 1990).
An alternative to promethazine in the case o f rashes 
caused by allergies might be chlorpheniramine (only 
for those children who are over 1 year o f age). Topical 
corticosteroids such as hydrocortisone (an over the 
counter medicine at 0.1% strength) might also be 
applied in cases o f allergic dermatitis.
The lack o f knowledge in over a third o f pharmacists 
was unexpected because o f their years o f training in 
basic and clinical pharmacology and therapeutics. This 
was perhaps, in part, due to a lack o f pursuit of 
continuous education by practising pharmacists. Non­
pharmacist personnel's lack o f knowledge about the 
minimum age especially among pharmacy assistants 
was somewhat expected because o f their lack basic 
training in pharmacology and drugs. Several studies 
supported the existence o f such high levels of 
ignorance about drugs among pharmacy assistants 
(Mwakutuya, 2005).
Conclusion
There was considerable inappropriate use o f 
promethazine, Stopayne* and Goldgesic* syrups in 
children less than 3 years old in Harare. This was 
evidenced by the fact that 53.70% o f interviewed 
parents were administering these syrups to children 
less than 2 years old. Also, o f the parents who 
administered these syrups to their children about 7.7% 
(3/39) did so for sedation purposes.
Recommendations
Training o f all personnel who work in a pharmacy 
should be regulated and be made mandatory, in order to 
protect patients' health. The classification of
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promethazine, Stopayne® and Goldgesic® syrups ought 
to be changed from pharmacy drugs to pharmacist- 
initiated medicines (PIM) or prescription preparation 
(PP). The potential risks o f administration of 
promethazine to infants outweigh any possible 
therapeutic benefit and we therefore urge doctors, 
pharmacists, and parents to avoid its use in infancy.
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